MEM Memphasys Limited
Healthcare · Medical Devices
· website
$0.01
52wk 0.00 – 0.01
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Memphasys Limited
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$21.61M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
0.49
EV / EBITDA
-7.00
Price / Book
7.00
ROE
-87.4%
Operating margin
-13,617.2%
Net margin
0.0%
Total cash
$411,431
Total debt
$4.37M
Current ratio
0.14
Debt / Equity
1.09
Free cash flow
$-349,534
Avg volume
3.47M
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income—
- Net income—
- Diluted EPS-0.00
- Free cash flow—
- Net debt—